Kyoto University

Other

Kinopharma, Inc.

Tokyo Medical and Dental University

Tobishi Yakuhin Kogyo Kabushiki Kaisha

Kagoshima University

Masatoshi Hagiwara

Takamitsu Hosoya

Masaaki Suzuki

Suguru Yoshida

Tsutomu Inoue

Takashi Inaba

Tomohiko Ishikawa

Masayuki Yuasa

Osamu Sakuma

Tadashi Morita

Isao Umezawa

Tadashi Toshioka

Takeshi Fukuhara

Hiroshi Onogi

Kenji Naitoh

Yuto Sumida

Hiroyoshi Hidaka

Isao Kii

Masahiko Ajiro

Takashi Kurihara

Masafumi Matsuo

Hiroko Koyama

Atsushi Nishida

Naoyuki Kataoka

Toshiyuki Hiramatsu

Akihide Takeuchi

Hidehito Kuroyanagi

Masayasu Toyomoto

Horoyoshi Hidaka

Akiko Kobayashi

Tetsunori Sakamoto

Provided is a method for preventing, ameliorating, suppressing the progression of, and/or treating a tumor caused by a tumor virus, the method including the step of administering, to a subject, an effective amount of a component that targets a gene product of the tumor virus.

Tumor suppression

A pharmaceutical composition for genetic diseases caused by an aberrant splicing regulation is provided. Provided are a pharmaceutical composition for preventing, ameliorating, suppressing progression of, and/or treating the genetic diseases caused by an aberrant splicing regulation, the pharmaceutical composition containing, as an active ingredient, a compound capable of suppressing an aberrant splicing regulation that contributes to the development or progression of genetic diseases caused by an aberrant splicing regulation, and a method for preventing, ameliorating, suppressing progression of, and/or treating the genetic diseases using a compound capable of suppressing an aberrant splicing regulation that contributes to the development or progression of genetic diseases caused by an aberrant splicing regulation.

Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities

Provided is a composition for activating neurogenesis, use of the composition, and a method for preventing, improving, inhibiting the development of, and/or treating a disease or the like of the central nervous system and or the peripheral nervous system using the composition. A composition for activating neurogenesis contains, as an active ingredient, a compound having an ability to inhibit phosphorylation activity of a protein kinase or a prodrug thereof, or a pharmaceutically acceptable salt thereof, and a composition for preventing, improving, inhibiting the development of, and/or treating a disease of the central nervous system and/or the peripheral nervous system, or for improving, inhibiting the development of, and/or treating a functional disorder of the central nervous system and/or the peripheral nervous system, the composition containing, as an active ingredient, a compound having an ability to inhibit phosphorylation activity of a protein kinase or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

Composition for activating neurogenesis

The present invention provides a compound and a pharmaceutical composition for neuropsychological disorders or malignant tumors, the use of the compound and the pharmaceutical composition, or a method for preventing, improving, inhibiting the development of, and/or treating neuropsychological disorders or malignant tumors with the use of the compound and the pharmaceutical composition. One or more embodiments disclose a compound expressed by the following general formula (I) or (II) or a pharmaceutically acceptable salt of the compound: 

Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor

A compound and a pharmaceutical composition for disease associated with an abnormal splice variant, use of the compound and the pharmaceutical composition, or a screening method of the compound and the pharmaceutical composition are provided. One or more embodiments disclose a compound expressed by the following formula (I) or (I') or prodrugs or pharmaceutically acceptable salts thereof. Another one or more embodiments disclose a screening method using a DNA construct that is fused, arranged, or constructed so as to express different reporter genes for a wild-type splice variant and an abnormal splice variant that contributes to the development or progression of disease; 

Method for screening substance capable of inhibiting abnormal splicing causative of onset or progress of disease

Provided is a pain-related compound, a pain-related pharmaceutical composition, and use of the same. Provided in one or more embodiments is a compound represented by Formula (I), a prodrug of the same, or a pharmaceutically permissible salt of any of the same. 

Pain-related compound and medical composition

An object of the present invention is to develop a new alternative splicing reporter system and to provide a method for detecting alternative splicing patterns in a mammalian multicellular organism more precisely, a method for identifying efficiently substances and gene regions that affect alternative splicing in a mammalian multicellular organism, and the like by utilizing the alternative splicing reporter system. Specifically, the present invention relates to a method for detecting alternative splicing in a mammalian multicellular organism, and a method for identifying substances and gene regions that affect alternative splicing in a mammalian multicellular organism, which use a DNA construct in which at least two different reporter genes are inserted into a specific gene that undergoes alternative splicing, or a combination of DNA constructs (a combination of at least two different DNA constructs) in which DNA construct a reporter gene is inserted into a specific gene that undergoes alternative splicing.

Transgenic reporter system that reveals expression profiles and regulation mechanisms of alternative splicing in mammalian organisms

An object of the present invention is to provide a prophylactic or ameliorating agent for a genetic disease that is caused by a mutation in an exon of a gene and is capable of forming a functional truncated protein by skipping of the exon comprising the mutation. The prophylactic or ameliorating agent used in the present invention is a prophylactic or ameliorating agent for a genetic disease that is caused by a mutation in an exon of a gene and is capable of forming a functional truncated protein by skipping of the exon comprising the mutation, wherein the prophylactic or ameliorating agent contains a compound having a molecular weight of 1500 or lower.

Prophylactic or ameliorating agent for genetic diseases

The present invention provides: (1) antiviral agents that act by reducing or inhibiting the activity of SR proteins, more specifically, (i) antiviral agents that act by enhancing dephosphorylation of SR proteins, and (ii) antiviral agents that act by inhibiting proteins that phosphorylate SR proteins; (2) antiviral agents that act by inhibiting the expression of SR proteins, and (3) antiviral agents that act by activating proteins that antagonize SR proteins. The present invention also provides compounds that inhibit SRPKs, which phosphorylate SR proteins. Such compounds inhibit the activity of SR proteins and have antiviral activities. Various new viruses including SARS have emerged, and thus the present invention provides long-lasting broad-spectrum antiviral agents applicable to new viruses.

Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity

Viruses, and particularly RNA viruses, have high mutation rates. Hence, antiviral agents that have been developed to date targeting protease or reverse transcriptase of viruses have quickly lost their effectiveness and resistant viruses have emerged. Also, in recent years, viral diseases caused by various new viruses such as SARS, avian influenza, and the hepatitis C have become social menaces. Therefore, the development of a novel antiviral agent that can cope with a virus resistant to an existing drug or a new virus and has a wide range of applications has been demanded. The present invention provides a novel anti-RNA viral agent and a method for use thereof. The present invention further provides an anti-RNA viral agent that is also effective against a new virus or a drug-resistant virus, and a method for use thereof.

Aniline derivative having anti-RNA viral activity

An object of the present invention is to develop a new alternative splicing reporter system and to provide a method for detecting alternative splicing patterns in a multicellular organism more precisely, a method for identifying efficiently substances and gene regions that affect alternative splicing in a multicellular organism, and the like by utilizing the alternative splicing reporter system. Specifically, the present invention relates to a method for detecting alternative splicing in a multicellular organism, and a method for identifying substances and gene regions that affect alternative splicing in a multicellular organism, which use a DNA construct in which at least two different reporter genes are inserted into a specific gene that undergoes alternative splicing, or a combination of DNA constructs (a combination of at least two different DNA constructs) in which DNA construct a reporter gene is inserted into a specific gene that undergoes alternative splicing.

Transgenic reporter system that reveals expression profiles and regulation mechanisms of alternative splicing in nematodes

The present invention provides a composition of treating, preventing abnormal splicing caused by the excessive kinase induction, which comprises TG003 and a method using the same of treating, preventing abnormal splicing caused by the excessive kinase induction.

Therapeutic composition of treating abnormal splicing caused by the excessive kinase induction

Method for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity

Growing community of inventors

Kyoto, Japan

Masatoshi Hagiwara